Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.42 |
| ▸ | CA9 | Q16790 | 5/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
| ▸ | F11 | P03951 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HCAR1 | Q9BXC0 | 5/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28647686 | 0.76 | PDE3B (0.45) | CA12CA9PDE3BPDE3AADORA2A | |
| SCHEMBL3729985 | 0.74 | ADORA1 (0.44) | CA12CA9PDE3BPDE3AADORA2A | |
| SCHEMBL587003 | 0.74 | KMT2A (0.45) | CA12CA9PDE3BPDE3AADORA2A | |
| SCHEMBL4136622 | 0.74 | PDE3B (0.47) | CA12CA9PDE3BPDE3AADORA2A | |
| SCHEMBL30549011 | 0.74 | HPGD (0.40) | CA12CA9PDE3BPDE3ACA1 | |
| SCHEMBL30039796 | 0.74 | HPGD (0.40) | CA12CA9PDE3BPDE3ACA1 | |
| SCHEMBL28837183 | 0.71 | ADORA2A (0.39) | CA12CA9ADORA2AADORA1SNCA | |
| SCHEMBL19233139 | 0.71 | CA12 (0.41) | CA12CA9PDE3BPDE3ACA1 | |
| SCHEMBL29547698 | 0.71 | CA12 (0.41) | CA12CA9PDE3BPDE3ACA1 | |
| SCHEMBL4136907 | 0.71 | CCR1 (0.48) | CA12CA9PDE3BPDE3ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2991992-B1 | QUINOLONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-07-25 | — | — | EP | disclosed |
| US-9540399-B2 | Quinolone derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2017-01-10 | — | — | US | disclosed |
| EP-2991992-A1 | QUINOLONE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2016-03-09 | — | — | EP | disclosed |
| US-20160060276-A1 | QUINOLONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-03-03 | — | — | US | disclosed |
| WO-2014178008-A1 | QUINOLONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-11-06 | — | — | WO | disclosed |
| WO-2008084324-A1 | NAPHTHYRIDINONE COMPOUND | PFIZER PRODUCTS INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008084324-A1 | NAPHTHYRIDINONE COMPOUND | PFIZER PRODUCTS INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| US-20080167319-A1 | 7-(4-(4-[3-CHLORO-2-(TRIFLUOROMETHYL)PHENYL]PIPERAZIN-1-YL)BUTOXY)-[1,8]-NAPHTHYRIDIN-2(1H)-ONE | PFIZER INC. | 2008-07-10 | — | — | US | disclosed |
| US-20080167319-A1 | 7-(4-(4-[3-CHLORO-2-(TRIFLUOROMETHYL)PHENYL]PIPERAZIN-1-YL)BUTOXY)-[1,8]-NAPHTHYRIDIN-2(1H)-ONE | PFIZER INC. | 2008-07-10 | — | — | US | disclosed |
| US-20080167319-A1 | 7-(4-(4-[3-CHLORO-2-(TRIFLUOROMETHYL)PHENYL]PIPERAZIN-1-YL)BUTOXY)-[1,8]-NAPHTHYRIDIN-2(1H)-ONE | PFIZER INC. | 2008-07-10 | — | — | US | disclosed |
| US-7160888-B2 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER LAMBERT COMPANY LLC (US) | 2007-01-09 | — | — | US | disclosed |
| US-20060287309-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | disclosed |
| US-20060287310-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | disclosed |
| EP-1660497-A1 | [ 1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | Warner-Lambert Company LLC (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005019215-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER-LAMBERT COMPANY LLC | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060276-A1 | QUINOLONE DERIVATIVES | NQO2, QARS1, RECQL | CA12 4847/4885CA9 4402/4885PDE3B 792/4885 |
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | DRD1, DRD2, DRD3 | CA12 4774/4885CA9 4298/4885PDE3B 1360/4885 |
| US-20080167319-A1 | 7-(4-(4-[3-CHLORO-2-(TRIFLUOROMETHYL)PHENYL]PIPERAZIN-1-YL)BUTOXY)-[1,8]-NAPHTHYRIDIN-2(1H)-ONE | BDNF, SCN7A, GRIN2C | CA12 3891/4885CA9 4244/4885PDE3B 1165/4885 |
| US-20060287309-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | DRD1, DRD2, DRD3 | CA12 4774/4885CA9 4298/4885PDE3B 1360/4885 |
| US-20060287310-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | DRD1, DRD2, DRD3 | CA12 4774/4885CA9 4298/4885PDE3B 1360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.